<Anchor>
Pfizer of the United States announced that the final clinical trial of the COVID-19 vaccine showed 95% prevention effect.
It was said that the effect was clear regardless of age, sex, and race, and it was predicted that if the vaccine became available, normal life would be possible after next summer.
Correspondent Kim Soo-hyung reports from Washington.
<Reporter>
There are 43,000 people in the world who have undergone phase 3 clinical trials for the COVID-19 vaccine conducted by US pharmaceutical company Pfizer and German pharmaceutical company Bio&Tech.
170 of the test participants actually contracted the coronavirus, but only 8 of those who received the vaccine candidate were infected.
The remaining 162 were people who had been given fake drugs.
The corona immunity effect reaches 95%.
[Ugur Sahin/Bio&Tech CEO: If everything goes well and the vaccine supply is systematic, we will be able to spend the normal summer and winter of 2021.] In
particular, Pfizer is prevented even in high-risk seniors aged 65 and over. The effectiveness exceeded 94%, and it was announced that the effect was evident regardless of age, gender and race.
Based on the results, Pfizer announced that it would apply for emergency use approval to the US Food and Drug Administration and the FDA soon.
[Aiza/US Secretary of Health and Welfare: We have two types of vaccines that are safe and effective.
The FDA will soon be able to approve use.
We are preparing to distribute it in the coming weeks.]
Pouch, the head of the National Institute of Allergy and Infectious Diseases, the highest authority in infectious diseases in the United States, said that if the FDA approves urgent use, he will get the vaccine without hesitation and recommend the vaccine to his family.